Introduction
Orthotopic heart transplantation is an established treatment for heart failure refractory to medical treatment due to coronary artery disease or dilated cardiomyopathy. ' The problems of rejection have, to some extent, been overcome with the introduction of cyclosporin A and right ventricular biopsy to monitor immunosuppression. Nevertheless, rejection and infection, both manifestations of failure to control and monitor adequately immune function, remain the commonest causes of death in the first year after heart transplantation. Long term survival is principally limited by the development of coronary occlusive disease. 2 Combined heart and lung transplantation for end stage pulmonary vascular disease and chronic lung disease effectively started in the 1980s, with the introduction of cyclosporin A, an immunosuppressive agent without adverse effects on anastomotic healing. Previous attempts, including some single lung transplantations, produced poor results. Heart and lung transplantation is performed for both primary and secondary pulmonary hypertension3 and end stage parenchymal lung disease.4 Some centres offer double lung transplantation for the latter, with the benefit of the patients being able to retain their own heart. Single lung transplantation is suitable for fibrotic lung disease and emphysema, where there is no risk of infection from the remaining contralateral lung.5 As with other solid allografts, the main complications in heart and lung transplant recipients are rejection and infection. In combined grafts the lungs reject earlier and more vigorously than the heart,6 and improvement in survival has been achieved by monitoring rejection episodes with the aid of transbronchial lung biopsy. 7 8 The lungs are very prone to infections with common and opportunistic pathogens and have a much higher infection rate than other allografts, adding to problems of diagnosis and management. 9 Obliterative bronchiolitis is the main limiting factor for long term survival.'0 Most of the pathology of heart and lung transplantation is dealt with in the recognised United Kingdom transplantation centres, but with the increasing pool of transplant recipients, some of the biopsy and necropsy pathology may be seen elsewhere.
Rejection in the heart
Billingham devised a simple grading system for rejection in the heart" in heart transplantation. The interpretation and relevance of the various morphological changes seen Pathology of heart and heart and lung transplantation Figure 10 Grade A3: changes of A2 with extension into surrounding interstitium. Bronchioles included in these specimens showed lymphoid infiltration, the complete grade is therefore A3a. Figure I1 Grade A4: extensive perivascular, interstitial, and intra-alveolar lymphoid infiltrates with intra-alveolarfibrin. Bronchial and bronchiolar lymphoid infiltration was also present, the complete grade is therefore A4a,c. obvious in haematoxylin and eosin stained sections of transbronchial biopsy specimens, with numerous organisms in a Grocott methenamine silver stain. The associated inflammation may be non-specific or granulomatous. ' 
